Top Markets
Coin of the day
RLS Global AB (publ) RLS Global AB (publ)

RLS Global AB (publ)

RLS
Rank in Stocks #35382
RLS Global AB (publ) is a Swedish medical technology firm that specializes in... RLS Global AB (publ) is a Swedish medical technology firm that specializes in developing and commercializing therapeutic products for conditions within wound and oral care. Among its key offerings are ChloraSolv, a treatment specifically designed for chronic diabetic foot and leg ulcers in diabetic patients, and CariSolv, a unique gel employed for the removal of dental caries. Established in 1996, the company maintains its headquarters in MΓΆlndal, Sweden.
Share Price
$0.04981532
Last synced: 2024-07-12
Market Cap
$3.99M
Change (1 day)
13.82%
Change (1 year)
0.00%
Country
SE
Trade RLS Global AB (publ) (RLS)

Category

P/E ratio for RLS Global AB (publ) (RLS)
P/E ratio as of 2026 TTM: 0
According to RLS Global AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for RLS Global AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.